GLEOSTINE

LOE Approaching

lomustine

NDAORALCAPSULE
Approved
Aug 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT06336291Phase 2Recruiting

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Started May 2024
90 enrolled
Glioblastoma
NCT04933942Phase 2Withdrawn

Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

Started Sep 2022
0
First Progression of MGMT Promoter-methylated Glioblastoma
NCT05304663Phase 1Withdrawn

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Started Jun 2022
0
Glioblastoma
NCT04573192Phase 1/2Recruiting

A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Started Feb 2021
142 enrolled
Glioblastoma
NCT02343406Phase 2Completed

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Started Feb 2015
266 enrolled
Glioblastoma